What is the recommended starting dose and titration schedule for Vyvanse (lisdexamfetamine) in children, adolescents, and adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vyvanse Dosing Recommendations

Start Vyvanse at 30 mg once daily in the morning for all patients aged 6 years and older (both children and adults), then titrate in 10-20 mg increments at weekly intervals up to a maximum of 70 mg daily. 1

Starting Dose

The FDA-approved starting dose is 30 mg once daily for ADHD treatment in:

  • Pediatric patients ≥6 years old
  • Adolescents
  • Adults

This represents a higher starting dose than the traditional immediate-release amphetamine recommendation of 2.5 mg 2, reflecting Vyvanse's prodrug formulation and extended-release properties.

Titration Schedule

Increase by 10 mg or 20 mg increments at approximately weekly intervals based on symptom response and tolerability 1. Research supports that dose titration can be accomplished effectively on a 7-day basis, though in urgent situations may be done as quickly as 3 days 3.

The systematic approach:

  • Week 1: 30 mg
  • Week 2: 40-50 mg (if needed)
  • Week 3: 50-60 mg (if needed)
  • Week 4: 60-70 mg (if needed)

Maximum Dose

70 mg once daily is the maximum recommended dose for ADHD 1

Important Dose Adjustments:

Renal impairment requires dose reduction:

  • Severe renal impairment (GFR 15-29 mL/min/1.73 m²): Maximum 50 mg daily
  • End-stage renal disease (GFR <15 mL/min/1.73 m²): Maximum 30 mg daily 1

Administration Details

  • Timing: Take in the morning with or without food
  • Avoid afternoon doses due to insomnia risk 1
  • Capsules: Can be swallowed whole OR opened and mixed with yogurt, water, or orange juice (consume immediately, do not store)
  • Chewable tablets: Must be chewed thoroughly before swallowing
  • Do not divide doses: One complete capsule/tablet per day only 1

Clinical Monitoring During Titration

Pre-treatment Requirements:

  • Cardiac assessment (history, family history of sudden death/arrhythmia, physical exam) 1
  • Screen for tics or Tourette's syndrome 1
  • Baseline vital signs (blood pressure, pulse, height, weight) 2

During Titration (Weekly):

  • Assess ADHD symptoms using parent and teacher reports (rating scales helpful) 2
  • Monitor for side effects: decreased appetite, insomnia, irritability, headache 2
  • Check vital signs regularly 2
  • Maintain weekly contact (office visit or telephone) during dose adjustment phase 2

Evidence-Based Considerations

More than 70% of children respond to methylphenidate when a full dose range is systematically tried 3, and over 90% respond to one of the stimulant classes when both methylphenidate and amphetamine formulations are attempted 3. Research with Vyvanse specifically demonstrates:

  • Dose-dependent improvements in ADHD symptoms across the 30-70 mg range 4
  • Duration of action: 13 hours in children, 14 hours in adults 5
  • Higher baseline severity may benefit more from higher doses, particularly for hyperactive-impulsive symptoms 4

Common Pitfalls to Avoid:

  1. Don't calculate dose by weight - stimulant response is not reliably related to body weight 3
  2. Don't stop at inadequate doses - systematically titrate through the full range before declaring treatment failure 2
  3. Don't exceed maximum doses without reconsidering the diagnosis - if 70 mg doesn't help, more is not necessarily better; consider alternative medications or psychosocial interventions 2
  4. Monitor cardiovascular effects more closely in stimulant-naïve patients - research suggests more cardiovascular effects in treatment-naïve children compared to those previously exposed to stimulants 6

Side Effect Profile:

Most adverse events are mild to moderate and occur during the first 4 weeks 7, 8:

  • Decreased appetite (most common, ~49%)
  • Insomnia (~13%)
  • Weight decrease (~18%)
  • Headache (~6%)
  • Irritability (~9%)

Vital sign changes at therapeutic doses show mean increases of approximately 7 bpm pulse, 3-4 mmHg systolic BP, and 3 mmHg diastolic BP 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.